Personalis

Personalis OCF Margin

The Operating Cash Flow Margin of Personalis (PSNL) as of Oct 11, 2026 is -107.61 %. In the previous year, Operating Cash Flow Margin was -53.36 % — a change of 101.66% (lower).

OCF Margin

-107.61 %

YoY

101.66%

Last updated:

Operating Cash Flow Margin of Personalis is 2025 -107.61 % . Operating Cash Flow Margin of Personalis was 2024 -53.36 % . It decreases by 101.66% lower compared to the previous year.

The Personalis OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
14.75 USD
Jan 1, 2019
-27.71 USD
Jan 1, 2020
-54.23 USD
Jan 1, 2021
-82.85 USD
Jan 1, 2022
-107.97 USD
Jan 1, 2023
-76.56 USD
Jan 1, 2024
-53.36 USD
Jan 1, 2025
-107.61 USD
The Personalis OCF Margin history
YEAROCF MarginYoY
-107.61 %+101.66%
-53.36 %-30.30%
-76.56 %-29.09%
-107.97 %+30.33%
-82.85 %+52.76%
-54.23 %+95.71%
-27.71 %-287.85%
14.75 %+377.78%
3.09 %—
Access this data via the Eulerpool API

Personalis Stock analysis

What does Personalis do? Personalis Inc is a diagnostic company specializing in the development of tests for personalized medicine. The company was founded in 2011 by Dr. Richard Chen and Dr. Erin Newburn and is headquartered in Menlo Park, California. They initially focused on developing genomic tools for cancer diagnosis and treatment but have expanded their offerings to include tests for rare genetic diseases, immunotherapies, and precision oncology drugs. They work closely with pharmaceutical and biotechnology companies as well as academics to develop innovative therapeutic approaches. Their business model is based on making genomics biology usable for personalized medicine and clinical research. They have a wide portfolio of genomic-based solutions for personalized medicine, including tests for tumor mutations, tumor-specific neoantigens, rare genetic diseases, and personalized immunotherapy. They also offer customized genomic solutions for pharmaceutical and biotechnology companies. Personalis Inc aims to establish personalized medicine quickly and effectively to provide the best possible outcome for patients. Personalis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Personalis stock

Operating Cash Flow Margin of Personalis is -107.61 % in 2025.

Operating Cash Flow Margin of Personalis changed from -53.36 % to -107.61 %, representing a 101.66% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Personalis since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Personalis with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

Margins — Personalis

All Key Metrics — Personalis